Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...

and reduced risk of clinical worsening events for people with WHO group 1 pulmonary hypertension. These "dramatic" benefits ...

2 For this analysis, the investigators used these disease classifications of pulmonary hypertension: Group 1: pulmonary vascular resistance (PVR) above 2 WU and a max left ventricle filling ...

[80] ARIES-1 randomized 202 patients with PAH to either placebo or ambrisentan ... achieved an improvement in 6MWD and the combined group achieved a significant improvement in time to clinical ...

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.